Caregen Co., Ltd.

Abion Inc.

Enhancedbio Inc.

Genopharm Inc.

Caragen Co., Ltd.

Xcell Therapeutics Inc.

Young Deug Kim

Eun Mi Kim

Jun Young Choi

Yong Ji Chung

Young Kee Shin

Sang Su Song

Yong-Ji Chung

Young Ji Chung

Kyoung Mi Cho

Chung Ryul Kim

Ju Ho Lee

Young Jin Lee

Eun Ji Park

Jeong Jin Choi

Su Mi Kim

Tae Eun Kim

Hun Soon Jung

Sung Youl Hong

Sung Su Kim

Il Hwa Hong

Deuk Ae Kim

Sang Gyu Park

Ha Yeon Park

Byoung Jun Park

Jong Chan Ahn

Yeong Mun Kim

Sang Min Han

Ui Ii Lee

Jin Seuk Kim

Yejin Kim

Young Key Shin

Il Hong

Heo Bin Yang

Jun-Young Choi

Ui Il Lee

The present invention is to provide a 3D cartilage organoid block prepared by differentiating mesenchymal stem cells into 3D spheroid cartilage tissues, a basic unit for the 3D cartilage spheroid block. The inventors found that both the amount of GAG matrix and the expression of the collagen type2 increased. Therefore, the method of this invention provides clinically applicable cartilage tissues by effectively enhancing the function of the cartilage differentiation constructs according to 2D culture. The 3D cartilage organoid block can be usefully applied to the area, such as, articular cartilage regeneration and plastic surgery, where cartilage tissues restoration is required.

Method for preparing 3D cartilage organoid block

The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same. The human interferon-beta variant has superior activity or functions compared with natural interferon-beta, and the productivity of the immunocytokine according to the present invention is excellent. In addition, the immunocytokine according to the present invention can be favorably used as a target therapeutic agent for multiple sclerosis or cancer since the immunocytokine express both of functions of the interferon-beta and characteristics of the antibody binding to a specific antigen.

Human interferon-beta variant conjugated immunocytokine and method for preparing same

An immune conjugate according to the present invention provides a pharmaceutical composition, which can be used in the target-oriented drug treatment by conjugating a dendron allowing a plurality of drugs to be bound to a surface thereof and a target-directed antibody, and especially, can deliver high concentrations of drugs in a tumor-specific manner to exhibit a strong anticancer effect by conjugating a hydrophilic dendron, to which a plurality of anticancer drugs are bound, to an antibody.

Immune conjugate having dendron conjugated to antibody and use thereof

The present invention relates to a composition for preventing or treating diseases associated with human papillomavirus (HPV), and more specifically, cancer associated with HPV, and even more specifically, cervical cancer. The nucleotide sequence of the present invention, the sequence in which the base thereof is modified, and a specific combination thereof can be useful in a composition for effectively treating diseases associated with HPV infection by greatly inhibiting the expression of the E6/E7 gene of HPV type 16 or 18.

Composition for treating cancer associated with HPV infection

The present invention relates to a GFP-CAP peptide having an amino acid sequence derived from TGF-&#x3b2;1 (transforming growth factor-&#x3b2;1) and a cell adhesion sequence, wherein the amino acid sequence derived from TGF-&#x3b2;1 consists of the amino acid sequence of SEQ ID NO:1 and the TGFP-CAP peptide is represented by the following formula I: Ile-Trp-Ser-Leu-Asp-Thr-Gln-Tyr-Cell adhesion sequence (I). The TGFP-CAP peptide of the present invention exhibits excellent anti-angiogenic activity. In addition, the TGFP-CAP peptide of the present invention prevents effectively melanin generation in skin to have skin whitening effects. The present peptide shows much higher stability and permeability to skin than natural-occurring TGF-&#x3b2;1. Such plausible activities and safety of the present peptide enable advantageously to application to drugs, quasi-drugs and cosmetics.

TGFP-CAP peptide and its uses

Disclosed are a noggin-derived peptide and a composition containing the same for promoting hair growth, improving skin conditions, providing anti-inflammatory function, or preventing or treating bone diseases. The disclosed noggin-derived peptide performs a function identical or similar to that of natural human noggin and is superior in stability and skin permeability as compared thereto. The composition containing the peptide of the present disclosure as an active ingredient exhibits remarkably superior effects in treating, preventing or improving growth factor-related symptoms, e.g. hair loss, skin conditions or cut, or treating, preventing or improving growth factor overexpression-related symptoms. Therefore, the superior activity and stability of the peptide of the present disclosure are greatly advantageous in application to medicine, quasi-drugs and cosmetics.

Noggin-derived peptide and use thereof

The present invention relates to a transforming growth factor-beta (TGF-&#x3b2;)-mimicking peptide containing a particular amino acid sequence and a composition for preventing or treating TGF-&#x3b2;-effective disorders or conditions using the same. The peptide of the present invention may be much higher stability than natural-occurring TGF-&#x3b2; and improve drawbacks caused by high molecular weight of natural-occurring TGF-&#x3b2;. The peptide of this invention can be advantageously applied to treatment or improvement of TGF-&#x3b2;-effective disorders or conditions and have excellent efficacies on skin whitening and wrinkle improvement.

Peptide having activity of transforming growth factor and production method therefor

The present invention relates to a growth factor-mimicking peptide having an activity of the growth factor, and a composition and a method for improving skin conditions or for treating a wound using the same. The growth factor-mimicking peptides of this invention have identical functions or actions to natural-occurring human growth factor, and much better stability and skin penetration potency than natural-occurring growth factor. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on the treatment, prevention and improvement of diseases or conditions demanding growth factor activities. In addition, excellent activity and stability of the peptides of this invention can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.

Growth factor-mimicking peptides and uses thereof

The present invention relates to a peptide having the activity of insulin like growth factor-1 (IGF-1) and derived from IGF-1, a composition for improving skin conditions or treating a periodontal disease comprising the peptide. The IGF-1 mimicking peptides of this invention have identical functions or actions to natural-occurring IGF-1 and much better stability and skin permeation than natural-occurring IGF-1. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on the treatment, prevention and improvement of diseases or conditions demanding IGF-1 activities. In addition, the peptides of this invention can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.

Methods of use for peptides having activities of insulin like growth factor-1

The present invention relates to peptides comprising the amino acid sequence represented by the following formula 1 and having the activities of epidermal growth factor and their uses: Cys-Met-Tyr-Ile-Glu-Linker-Arg-Gly-Asp (1) The EGF-mimicking peptides of the present invention possess identical functions or activities to natural-occurring human EGF and are able to promote the generation of autocrine EGF in cells. In addition the peptides of the present invention are much higher stability and skin penetration potency than natural-occurring EGF. Therefore, the composition containing the peptide exhibits excellent treatment and prevention efficacies on diseases or conditions demanding EGF activities, and can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.

Peptides having activities of epidermal growth factor and its uses

The present invention relates to a peptide comprising a specific amino acid sequence possessing human thymosin &#x3b2;-4 (T&#x3b2;4) activities and its uses. The peptide of this invention has identical or similar functions or actions to human T&#x3b2;4 and its biological activity is almost identical to natural-occurring T&#x3b2;4. In addition, the peptide of this invention exhibits much higher stability and skin permeation than natural-occurring T&#x3b2;4. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in thymosin &#x3b2;-4-effective disorders or conditions. In addition, the peptide of this invention can be advantageously applied to drugs, cosmetics, toothpaste and compositions for mouth cleaning and caring, most preferably, cosmetics. Specifically, the peptide of this invention is advantageously applied to cosmetics for promoting hair growth.

Peptides for promoting hair growth and improving wrinkle and cosmetic compositions comprising the same

Provided is a method for improving a skin condition or treating a periodontal disease, which includes administering to a subject a composition including a basic fibroblast growth factor-derived peptide as an active ingredient. The present method effectively improves skin conditions and treats periodontal diseases. In addition, the present peptides can be applied to pharmaceutical compositions, cosmetics, toothpaste and compositions for mouth cleaning and care.

Method for improving skin conditions

Growing community of inventors

Sihung-si, South Korea

Young Deug Kim